{"title":"诺华以15.3亿美元收购Fougera制药公司，山德士成为全球最大的非专利皮肤科公司","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1741","DOIUrl":null,"url":null,"abstract":"Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i5.1741\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"33 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i5.1741\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i5.1741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Novartis’ Sandoz to Become Largest Generic Dermatology Company with US$1.53 B Fougera Pharmaceuticals Acquisition
Novartis’ generic drug unit Sandoz has agreed to acquire Fougera Pharmaceuticals, the former US dermatology business of Nycomed, for US$1.53 B in cash in order to become the leading player in the global generic dermatology market. Fougera reported sales of US$429 M in 2011, most of which came from the US, and Novartis aims to expand the company’s product sales globally. The acquisition will also provide the Swiss company with in-house expertise in topical dermatological products.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
